CYCN
Price
$2.59
Change
-$0.06 (-2.26%)
Updated
Aug 1 closing price
Capitalization
9.24M
PALI
Price
$1.01
Change
-$0.01 (-0.98%)
Updated
Aug 1 closing price
Capitalization
5.1M
Interact to see
Advertisement

CYCN vs PALI

Header iconCYCN vs PALI Comparison
Open Charts CYCN vs PALIBanner chart's image
Cyclerion Therapeutics
Price$2.59
Change-$0.06 (-2.26%)
Volume$21.47K
Capitalization9.24M
Palisade Bio
Price$1.01
Change-$0.01 (-0.98%)
Volume$192.9K
Capitalization5.1M
CYCN vs PALI Comparison Chart in %
Loading...
CYCN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PALI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CYCN vs. PALI commentary
Aug 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYCN is a Hold and PALI is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 03, 2025
Stock price -- (CYCN: $2.59 vs. PALI: $1.01)
Brand notoriety: CYCN and PALI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYCN: 54% vs. PALI: 28%
Market capitalization -- CYCN: $9.24M vs. PALI: $5.1M
CYCN [@Biotechnology] is valued at $9.24M. PALI’s [@Biotechnology] market capitalization is $5.1M. The market cap for tickers in the [@Biotechnology] industry ranges from $213.98B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYCN’s FA Score shows that 1 FA rating(s) are green whilePALI’s FA Score has 1 green FA rating(s).

  • CYCN’s FA Score: 1 green, 4 red.
  • PALI’s FA Score: 1 green, 4 red.
According to our system of comparison, PALI is a better buy in the long-term than CYCN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYCN’s TA Score shows that 3 TA indicator(s) are bullish while PALI’s TA Score has 4 bullish TA indicator(s).

  • CYCN’s TA Score: 3 bullish, 6 bearish.
  • PALI’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, PALI is a better buy in the short-term than CYCN.

Price Growth

CYCN (@Biotechnology) experienced а -9.31% price change this week, while PALI (@Biotechnology) price change was -12.93% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.14%. For the same industry, the average monthly price growth was +15.55%, and the average quarterly price growth was +36.18%.

Reported Earning Dates

CYCN is expected to report earnings on May 06, 2025.

PALI is expected to report earnings on May 12, 2025.

Industries' Descriptions

@Biotechnology (+0.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CYCN($9.24M) has a higher market cap than PALI($5.1M). CYCN YTD gains are higher at: -19.453 vs. PALI (-38.788). CYCN has higher annual earnings (EBITDA): -3.47M vs. PALI (-13.13M). PALI has more cash in the bank: 7.23M vs. CYCN (3.64M). CYCN has less debt than PALI: CYCN (0) vs PALI (58K). CYCN has higher revenues than PALI: CYCN (2.08M) vs PALI (0).
CYCNPALICYCN / PALI
Capitalization9.24M5.1M181%
EBITDA-3.47M-13.13M26%
Gain YTD-19.453-38.78850%
P/E RatioN/A0.02-
Revenue2.08M0-
Total Cash3.64M7.23M50%
Total Debt058K-
FUNDAMENTALS RATINGS
CYCN vs PALI: Fundamental Ratings
CYCN
PALI
OUTLOOK RATING
1..100
7994
VALUATION
overvalued / fair valued / undervalued
1..100
19
Undervalued
20
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9699
PRICE GROWTH RATING
1..100
8945
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CYCN's Valuation (19) in the null industry is in the same range as PALI (20). This means that CYCN’s stock grew similarly to PALI’s over the last 12 months.

CYCN's Profit vs Risk Rating (100) in the null industry is in the same range as PALI (100). This means that CYCN’s stock grew similarly to PALI’s over the last 12 months.

CYCN's SMR Rating (96) in the null industry is in the same range as PALI (99). This means that CYCN’s stock grew similarly to PALI’s over the last 12 months.

PALI's Price Growth Rating (45) in the null industry is somewhat better than the same rating for CYCN (89). This means that PALI’s stock grew somewhat faster than CYCN’s over the last 12 months.

PALI's P/E Growth Rating (100) in the null industry is in the same range as CYCN (100). This means that PALI’s stock grew similarly to CYCN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CYCNPALI
RSI
ODDS (%)
N/A
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
N/A
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
N/A
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
89%
Bullish Trend 3 days ago
79%
Advances
ODDS (%)
Bullish Trend 24 days ago
85%
Bullish Trend 7 days ago
86%
Declines
ODDS (%)
Bearish Trend 5 days ago
89%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 3 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
CYCN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PALI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NB3.160.34
+12.06%
NioCorp Developments Ltd
RVTY88.230.33
+0.38%
Revvity
TNDM15.40-0.18
-1.16%
Tandem Diabetes Care
PAHC26.11-0.39
-1.47%
Phibro Animal Health Corp
INM2.39-0.04
-1.65%
InMed Pharmaceuticals Inc

CYCN and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYCN has been loosely correlated with HRTX. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if CYCN jumps, then HRTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYCN
1D Price
Change %
CYCN100%
-2.13%
HRTX - CYCN
41%
Loosely correlated
-2.31%
GDTC - CYCN
30%
Poorly correlated
-2.66%
FATE - CYCN
29%
Poorly correlated
-2.73%
IBIO - CYCN
25%
Poorly correlated
-3.09%
PALI - CYCN
24%
Poorly correlated
-0.98%
More

PALI and

Correlation & Price change

A.I.dvisor indicates that over the last year, PALI has been closely correlated with RNAC. These tickers have moved in lockstep 81% of the time. This A.I.-generated data suggests there is a high statistical probability that if PALI jumps, then RNAC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PALI
1D Price
Change %
PALI100%
-0.98%
RNAC - PALI
81%
Closely correlated
-3.75%
AGEN - PALI
81%
Closely correlated
-2.90%
NCNA - PALI
81%
Closely correlated
-8.86%
TAOX - PALI
81%
Closely correlated
-5.37%
ALLR - PALI
76%
Closely correlated
-2.88%
More